G70.0
Conditions
Interventions
Group 1: Patients with generalized myasthenia gravis who started therapy with a complement-inhibitor (eculizumab or ravulizumab) during a myasthenic crisis or severe exacerbation that required ICU/IMC
Sponsors
Charité - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - AchR-Ab+ generalized myasthenia gravis (defined in this project as either serologic antibody or cell-based-assay antibody or immunohistochemic proof of complement deposits at the neuromuscular junction in a muscle biopsy) - presence of a myasthenic crisis (MGFA V) or severe exacerbation with involvement of the pharyngeal and/or respiratory muscles (MGFA IVb) that requires treatment in ICU or IMC setting -start of therapy with either eculizumab or ravulizumab during the myasthenic crisis or severe exacerbation (while MGFA was V or IVb)
Exclusion criteria
Exclusion criteria: - presence of a cholinergic crisis without a diagnosis of myasthenia gravis - presence of a different myasthenic syndrome such as lambert eaton myasthenic syndrome or congenital myasthenic syndrome - the myasthenic crisis started less than 4 weeks after thymectomy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients who were discharged from ICU/IMC 6 weeks after starting the complement-inhibitor therapy. | — |
Countries
Germany
Contacts
Public ContactAndreas Meisel
Charité - Universitätsmedizin Berlin
Outcome results
None listed